Proven hereditary angioedema (HAE) attack prevention in the palm of your hand

ORLADEYO® provides meaningful HAE attack prevention

In a 3-part study of 120 adolescents and adults with HAE, 40 were given ORLADEYO 150 mg, 41 were given ORLADEYO 110 mg, and 39 were given placebo.

People taking ORLADEYO 150 mg for 6 months (part 1) had a decrease in average attack rate of 3.1 to 1.3 attacks per month compared with a decrease of 2.9 to 2.4 attacks per month for those taking placebo

Among 21 people who took ORLADEYO 150 mg for a total of 24 months, their average number of attacks per month dropped considerably.a

Continued attack rate reduction over 2 years

More than half of people had 0 attacks in 16 of the last 17 months of treatment

aBased on data from an ad-hoc analysis of interim data (the trial investigators explored this trend after the trial was designed and before the final data analysis).
bAt 24 months, average attack rate was lowered by 86% compared with pretreatment for the 21 people who completed the full 24 months of treatment with ORLADEYO 150 mg.

The use of rescue therapy was cut by more than half, in people taking ORLADEYO® vs a placebo

cBased on data from an ad hoc analysis of the first 6 months of the study (part 1).

It's important to stick to the treatment plan you've made with your healthcare provider for the best change at a successful treatment experience It's important to stick to the treatment plan you've made with your healthcare provider for the best change at a successful treatment experience

Curious about ORLADEYO and want to learn more? Register for a class to learn about ORLADEYO and connect with the community

Sign up
Review the potential side effects of ORLADEYO